During this webinar, learn more about benefits and risks of changing primary components during product development and how a design of experiments approach can be used to address issues and risks.

Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $2,340 per patient for a 5-day treatment.

With Moderna on the precipice of launching a Phase III trial of 30,000 people for the COVID-19 vaccine mRNA-1273, the company is ramping up manufacturing capabilities and is partnering with Catalent.

Glass maker Corning will receive $204 million from the U.S. government to boost the manufacturing capacity of vials that will be used to store coronavirus vaccines and treatments.

A federal appeals court revived nationwide litigation accusing Roche Holding AG’s Genentech unit of failing to ensure that vials of the comapny’s Herceptin breast cancer drug contained the labeled amount of the active ingredient, and that the labels misstated the drug’s concentration and volume.

U.S. drugmaker Pfizer Inc. signed a long-term agreement with glass maker Corning Inc. to procure vials for storing drugs.